Galderma Continues Global Growth Ambition With Sculptra (injectable poly-L-lactic Acid) Re-launch in Europe
Updated protocol allows for faster and more convenient administration of
Sculptra
with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra (injectable poly-L-lactic acid) a collagen stimulator with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
Thursday, March 4, 2021 1:52PM IST (8:22AM GMT)
Updated protocol allows for faster and more convenient administration of
Sculptra® with the optional addition of lidocaine to increase patient comfort
Update is based on new data from physiochemical and clinical studies evaluating the safety and effectiveness of
Sculptra®
Virtual event held with European healthcare professionals to mark re-launch provided additional education and support on new protocol
Galderma today announced a European re-launch of
Sculptra
® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients.